TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Early Versus Standard Start of Anti-HIV Therapy for Treatment-Naive Adults in Haiti

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HIV-infected~* Received pre- and post-test counseling at the GHESKIO Centers~* CD4 count between 200 and 350 cells/mm3~* World Health Organization (WHO) Stage I, II, or III HIV disease~* Willing to use acceptable forms of contraception~Exclusion Criteria:~* WHO Stage IV HIV disease (AIDS)~* 7 or more days of cumulative ART prior to study entry OR on ART at time of study entry~* Active TB, if diagnostic work-up for TB is incomplete OR if decision to treat TB has not been made. More information on this criterion can be found in the protocol.~* Recurrent active TB OR history of interrupted or incomplete TB therapy. More information on this criterion can be found in the protocol.~* Has not been evaluated for latent TB and decision to treat latent TB with isoniazid has not been made. More information on this criterion can be found in the protocol.~* Requires ART in the next 3 months, in the opinion of the investigator~* Other serious medical illness requiring chronic maintenance therapy (e.g., hypertension, diabetes) UNLESS the individual has completed at least 14 days of therapy prior to study enrollment AND is clinically stable~* Any psychological condition (e.g., severe depression, schizophrenia) that, in the opinion of the investigator, may interfere with the study~* Any social condition (e.g., pending emigration, pending incarceration) that, in the opinion of the investigator, may interfere with the study~* Active drug or alcohol use that, in the opinion of the investigator, may interfere with the study~* Current inflammation of the pancreas~* Allergy/sensitivity to any of study drugs or their formulations~* Requires certain medications~* Enrolled in another therapeutic or interventional clinical trial~* Pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Randomly assigned group who will start an ART regimen of 3TC/ZDV and EFV twice daily at study entry
- B (Type: ACTIVE_COMPARATOR): Randomly assigned group who will delay beginning ART regimen of 3TC/ZDV and EFC twice daily until they develop clinical AIDS or their CD4 count drops below 200 cells/mm3

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bemiparin Versus Enoxaparin in the Prevention of Venous Thromboembolism Among ICU Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Sepsis , stroke , major burn , respiratory failure , traumatic brain injury , malignancy and post arrest who are intubated and mechanically ventilated on continuous IV sedation~Exclusion Criteria:~* Hypersensitivity to low molecular weight heparins , hypercoagulability , congenital or acquired bleeding disorder, prolongation of activated partial thromboplastin time or prothrombin time by 20% compared to normal values; thrombocytopenia (platelet count \<100,000/mm3); macroscopic hematuria; uncontrolled hypertension \[systolic blood pressure \>200 mmHg; diastolic blood pressure \>100 mmHg\]; impaired kidney function: serum creatinine \> 2.0 mg/ dL and bleeding gastrointestinal ulcer.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Enoxaparin 40 mg subcutaneous once daily (Type: ACTIVE_COMPARATOR): None
- Bemiparin 3500 IU subcutaneous once daily (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Oliceridine (TRV130) for the Treatment of Moderate to Severe Acute Pain After Bunionectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Has undergone primary, unilateral, first metatarsal bunionectomy (osteotomy and internal fixation) with no additional collateral procedures.~* Experiences a pain intensity rating of moderate to severe acute pain.~* Able to provide written informed consent before any study procedure.~Exclusion Criteria:~* ASA Physical Status Classification System classification of P3 or worse.~* Has surgical or post-surgical complications.~* Has clinically significant medical conditions or history of such conditions that may interfere with the interpretation of efficacy, safety, or tolerability data obtained in the trial, or may interfere with the absorption, distribution, metabolism, or excretion of drugs.~* Has previously participated in another TRV130 clinical study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Treatment 1 Oliceridine (Type: EXPERIMENTAL): None
- Treatment 2 Oliceridine (Type: EXPERIMENTAL): None
- Treatment 3 Oliceridine (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None
- Morphine (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>18 years of age.~* World Health Organization (WHO) Grade IV glioma with definitive resection prior to leukapheresis with residual radiographic contrast enhancement on most recent CT or MRI of \<1 cm in maximal diameter in any axial plane.~* Karnofsky Performance Status (KPS ) of \> 80% and a Curran Group status of I-IV.~Exclusion Criteria:~* Radiographic or cytologic evidence of leptomeningeal or multicentric disease at the time of enrollment.~* Prior conventional anti-tumor therapy other than steroids, RT, Avastin or TMZ.~* Pregnant or need to breast feed during the study period (Negative Beta-Human Chorionic Gonadotrophin \[HCG\] test required).~* Requirement for continuous corticosteroids above physiologic levels at time of first vaccination.~* Active infection requiring treatment or an unexplained febrile (\> 101.5o F) illness.~* Known immunosuppressive disease or human immunodeficiency virus infection.~* Patients with unstable or severe intercurrent medical conditions such as severe heart or lung disease.~* Allergic or unable to tolerate TMZ for reasons other than lymphopenia.~* Patients with previous inguinal lymph node dissection.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (first randomization) (Type: EXPERIMENTAL): Patients receive CMV-ALT IV over 45-90 minutes (course 1 only) and CMV pp65-LAMP mRNA-loaded DC (CMV-DC) vaccine intradermally and administered in equal portions to each inguinal region. Vaccination repeats every 1-3 weeks for up to 3 doses in the absence of unacceptable toxicity.
- Arm II (first randomization) (Type: EXPERIMENTAL): Patients receive CMV-DC vaccine intradermally and administered in equal portions to each inguinal region. Vaccination repeats every 1-3 weeks for up to 3 doses in the absence of unacceptable toxicity.
- Arm I (second randomization) (Type: EXPERIMENTAL): Within 6 to 24 hours prior to vaccination, patients undergo skin site preparation with unpulsed DCs at the vaccination site in one inguinal region. Patients then receive indium In 111-labeled CMV-DC.
- Arm II (second randomization) (Type: EXPERIMENTAL): Within 6 to 24 hours prior to vaccination, patients undergo vaccination skin site preparation in the opposite inguinal region with tetanus toxoid. Patients then receive 111 In-labeled CMV-DC.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Shifting Perspectives: Enhancing Outcomes in Anorexia Nervosa With CRT

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:Adolescents~1. Age 12-18~2. Currently meets Diagnostic and Statistical Manual-5 criteria for Anorexia Nervosa~3. Medically stable for outpatient treatment~4. Fluent in English~5. No co-morbid condition that would exclude participation~6. Medical clearance from primary care physician and permission to speak to Primary Care Physician about clinical issues~7. Biological parent or primary caregiver willing to engage in treatment and who live with the adolescent~Inclusion Criteria:Parents~1. Age \>18~2. Child with a diagnoses of AN~3. Both parents willing to participate~4. Fluent in English~5. No co-morbid condition that would exclude participation~Exclusion Criteria: Adolescent~1. Adolescent outside age range~2. Adolescent adopted~3. Pregnant adolescent~4. Presence of: pervasive developmental disability, psychosis, bipolar disorder, substance abuse, autism spectrum disorder, or intellectual disability~5. Presence of: a brain disorder or injury (such as TBI) that could impact the ability to engage in treatment~6. Use of anti-psychotic medication~7. Concurrent psychosocial therapy~Exclusion Criteria: Parents~1. Presence of: pervasive developmental disability, psychosis, bipolar disorder, substance abuse, autism spectrum disorder, or intellectual disability.~2. Presence of: a brain disorder or injury (such as TBI) that could impact the ability to engage in treatment~3. Use of anti-psychotic medication

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Family Based Treatment (FBT) (Type: ACTIVE_COMPARATOR): Families will receive 15 sessions of FBT alone.
- FBT w/ Parent-focused Cognitive Remediation Therapy (Type: EXPERIMENTAL): Family Based Treatment with Parent-focused Cognitive Remediation Therapy (CRT): Families will receive 15 sessions of parent focused CRT followed Family Based Treatment over six months.
- FBT w/Adolescent-focused Cognitive Remediation Therapy (Type: EXPERIMENTAL): Family Based Treatment with Adolescent-focused Cognitive Remediation Therapy (CRT): Families will receive 15 sessions of adolescent focused CRT followed by Family Based Treatment over six months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Exercise in Combination With Epoetin Alfa

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Those who were not at high risk for impending pathologic fracture or cord compression, as determined by magnetic resonance imaging and other radiology reports and physician assessments,and enrolled in Total Therapy treatment protocols were invited to participate in the study.~Exclusion Criteria:~Patients were excluded if they showed any of the following attributes/conditions:~* Inability to understand the intent of the study~* Current diagnosis with a major psychiatric illness~* Presence of microcytic or macrocytic anemia~* Uncontrolled hypertension~* Red cell transfusions within 2 weeks; and~* Recombinant epoetin alfa within 8 weeks of study enrollment.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Exercise (Type: EXPERIMENTAL): Study participants were computer randomized to an individualized exercise program. Participants were stratified within Arm according to whether or not they received thalidomide with heparin, and by age (60 and younger versus older than 60)
- usual care (Type: ACTIVE_COMPARATOR): Study participants were asked to remain as active as possible but not prescribed an individualized exercise program. Participants were stratified within Arm according to whether or not they received thalidomide with heparin, and by age (60 and younger versus older than 60)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Safety and Maximum Tolerated Dose of Axitinib in Combination With Radiotherapy for HCC

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age of 20-85 years, with ECOG performance 0-2.~* Advanced hepatocellular carcinoma (HCC), histologically or clinically diagnosed. (Multiple tumors, portal vein thrombosis, nodal metastasis or distant metastasis is allowed.)~* Unsuitable for resection, liver transplantation, radiofrequency ablation (RFA) or transarterial chemoembolization (TACE), or recurrent / refractory after prior local-regional treatment.~* ≥ One measurable tumor.~* Child-Pugh score A or B.~* Patients who fulfill all of the following criteria:~  1. Serum total bilirubin ≤ 3 mg/dL~ 2. Serum alanine transaminase (ALT) ≤ 5 times ULN~ 3. INR ≤ 2.20~ 4. Platelet count ≥ 50,000 /mm3~ 5. WBC count ≥ 3,000 /mm3 or ANC ≥ 1,500 /mm3~ 6. Serum creatinine ≤ 2.0 mg/dL~* Normal thyroid function confirmed.~* Absence of grant for sorafenib.~* Sorafenib failure or intolerability (if ever used).~Exclusion Criteria:~* Considered to have high risk of bleeding (e.g. active peptic ulcer, unstable esophageal/gastric varices, history of aneurysm, and requirement of anticoagulant therapy).~* Pre-existing uncontrolled hypertension (systolic \>140 mmHg, diastolic \>90 mmHg) or proteinuria ≧500 mg/24 hours.~* Prior history of coronary artery disease.~* The patient is participating in other clinical trials.~* Pregnant women.~* Patients with rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.~* Patients with non-healing wound.~* Requiring the use of potent CYP3A4/5 inhibitors or inducers (see Appendix).~* Other severe acute or chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation and in the judgment of the investigator would make the patient inappropriate for entry into this study.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Axitinib (Type: EXPERIMENTAL): Combined axitinib and radiotherapy (fixed strength)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Investigate the Influence of MK0859 on Blood Pressure (MK-0859-012)(COMPLETED)

Study Design Characteristics:
- Allocation: N/A
- Intervention Model: N/A
- Observational Model: N/A
- Primary Purpose: N/A
- Time Perspective: N/A
- Masking: N/A
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* You are between the ages of 45-75~* You are a man or non-pregnant woman~* You agree to not eat or drink fruit or fruit juices (orange, apple or grapefruit) for 2 weeks before starting study medication~Exclusion Criteria:~* You have smoked or used other nicotine-containing products (chewing tobacco) within the last 6 months~* You have used St. John's Wort or any products that include it within the last 2 weeks~* You have used herbal, organic, dietary or nutritional remedies within the last 2 weeks~* You have a history of drug allergies (anaphylaxis, angioedema)~* You have taken an investigational drug in another clinical trial within the last 4 weeks~* You have a history of cardiovascular disease including hypertension (high blood pressure)~* You have a history of renal disease~* You have a history of gall bladder disease or have had abnormal liver function tests~* You have a history of drug or alcohol abuse~* You drink more than 6 cups of caffeinated beverages a day (coffee, tea or cola)

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Antepartum Chronic Epidural Therapy (ACET) to Improve Blood Flow to the Uterus, Placenta and Baby in Pre-Eclampsia and Intrauterine Growth Restriction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* 1. Reliable gestational age based upon an ultrasound crown-rump length performed between 7 to 14 completed weeks gestation. If the ultrasound date matches the date of the last menstrual period (LMP) within 7 days, the LMP date is used, otherwise the ultrasound date is used.~  2. Gestational age at the time of enrollment between 28 to 32 weeks (based upon 1.) and need for in-hospital observation or treatment REGARDLESS of the study.~  3. Presence of uterine artery notching in ultrasound scan. 4. EITHER 4a or 4b (if both, the patient is enrolled as for 4a): 4a. Pre-eclampsia: Women must have criteria #1 and #2 Criterion #1: Hypertension (\> 140/90) at rest, measured twice, at least 6 hours apart.~Criterion #2: Proteinuria:~EITHER: At least 0.1 g/l in two random samples at least 6 hours apart. OR: At least 0.3g in a 24 hour collection.~4b Intrauterine growth retardation (IUGR): Women must have criteria #1 and #2. Criterion #1: Ultrasound abdominal circumference below 10th percentile. Criterion #2: Established IUGR for at least 2 weeks.~Exclusion Criteria:~* at the time of enrollment: active labor, severe pre-eclampsia, (resting blood pressure ≥ 160mmHg systolic or 110 diastolic, recorded on at least two occasions 6 hours apart), known fetal anomaly, intrauterine infection, placental anomalies (previa, abruption, circumvallate, infarction), twins, and refusal of consent.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: High Dose Daunorubicin Vs. Standard Dose Daunorubicin in Induction Treatment of AML

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with newly diagnosed AML or RAEB~* 15 years of age or older, but younger than 60 years of age~* Adequate hepatic and renal function~* Normal cardiac function with LVEF ≥ 50% on MUGA scan or echocardiogram~* Written informed consent~Exclusion Criteria:~* promyelocytic leukemia or chronic myelogenous leukemia~* significant infection~* prior chemotherapy history for leukemia

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- arm I (Type: ACTIVE_COMPARATOR): Cytarabine 200 mg/m2/d civ x 7 days Daunorubicin 45 mg/m2/d civ x 3 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tranexamic Acid in Clopidogrel Exposure to Decrease Hemorrhage and Transfusion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Patients requiring primary and isolated coronary artery bypass grafting with cardiopulmonary bypass~Exclusion Criteria:~* history of cardiac surgery~* hematocrit \<33%~* platelet count \<100,000/ml~* allergy to tranexamic acid~* recruited in other studies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- group ET (Type: EXPERIMENTAL): Patients receiving early CABG \<=7 days of the cessation of clopidogrel, treated with tranexamic acid with a bolus of 10 mg/kg after anesthetic induction and a maintenance of 10 mg/kg/h for the duration of surgery.
- group EP (Type: PLACEBO_COMPARATOR): Patients receiving early CABG \<= 7 days of the cessation of clopidogrel, treated with placebo(saline solution)
- group LT (Type: EXPERIMENTAL): Patients receiving late CABG \>7 days of the cessation of clopidogrel, treated with tranexamic acid with a bolus of 10 mg/kg after anesthetic induction and a maintenance of 10 mg/kg/h for the duration of surgery.
- group LP (Type: PLACEBO_COMPARATOR): Patients receiving late CABG \>7 days of the cessation of clopidogrel, treated with placebo(saline solution)
- group BT (Type: EXPERIMENTAL): Patients receiving CABG without preoperative clopidogrel exposure, treated with tranexamic acid with a bolus of 10 mg/kg after anesthetic induction and a maintenance of 10 mg/kg/h for the duration of surgery.
- group BP (Type: PLACEBO_COMPARATOR): Patients receiving CABG without preoperative clopidogrel exposure, treated with placebo(saline solution)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete